Investment bank Wedbush believes Zenas BioPharma is still being undervalued by the market, as investors obsess over the phase 3 INDIGO trial results for its lead drug obexelimab, particularly how it stacks up against Amgen's Uplizna. In a research note Friday, Wedbush argued that the real drivers of adoption may be the less glamorous factors: safety, steroid-sparing potential, infection risk, and total treatment costs.
What's the INDIGO Trial and Why Does It Matter?
INDIGO is a phase 3 clinical trial testing obexelimab in patients with IgG4-related disease, a chronic autoimmune condition. The trial's results are critical because they will determine whether obexelimab can compete with Uplizna, an approved treatment from Amgen. However, Wedbush contends that the market's focus on efficacy comparisons is too narrow.
In the biopharma world, formulary placement—the list of drugs that insurers and pharmacy benefit managers (PBMs) cover—often hinges on factors beyond just how well a drug works. Safety profiles, the ability to reduce steroid use, lower infection rates, and overall cost can be just as important. Wedbush believes obexelimab's profile in these areas could give it an edge, even if efficacy data are comparable.
Multiple Data Readouts on the Horizon
Wedbush also highlighted that Zenas has multiple data readouts scheduled over the next 12 months, which could shift investor attention away from the INDIGO debate. These upcoming catalysts include results from other trials of obexelimab in different indications, as well as potential updates on the drug's regulatory path. The bank argues that as these data points emerge, the market may begin to price in a more complete picture of obexelimab's potential.
This is a common pattern in biotech investing: a single trial can dominate sentiment, but a pipeline of catalysts can eventually broaden the narrative. For Zenas, the next year could be pivotal in demonstrating that obexelimab is more than just a one-trial wonder.
What It Means for Investors
For everyday investors, Wedbush's note suggests that Zenas BioPharma may be a case where the market is overlooking key details. The bank's argument is that the stock is mispriced because the market is too focused on one data point—the INDIGO efficacy comparison—while ignoring the real-world factors that drive drug adoption, such as safety and cost.
Investors should understand that biotech stocks are often volatile around trial results. However, Wedbush's analysis implies that if obexelimab's safety and cost advantages become clearer, the stock could re-rate higher. The upcoming data readouts could serve as catalysts to refocus attention on these factors.
It's also worth noting that Wedbush has a track record of identifying mispriced opportunities in the biotech space. For example, the bank recently commented on Staar Surgical's China sales showing signs of stabilization, and expected a softer Q2 for IMAX before a stronger second half. These calls show that Wedbush often looks beyond headline numbers to find value.
However, investing in biotech carries significant risk. Clinical trials can fail, regulatory decisions can be unpredictable, and competition from larger players like Amgen is intense. The broader biopharma sector has been driven more by company-specific results than by interest rates, as Morgan Stanley recently noted. That means Zenas's fate will largely depend on its own execution.
Wedbush's note does not guarantee that obexelimab will succeed, but it does highlight a potential disconnect between market perception and the drug's underlying value. Investors should watch for the upcoming data readouts and any updates on formulary discussions, as these could be the catalysts that close the gap.
